Editas Medicine, Inc. (EDIT)

3.08 0.00 (0.00%) USD  |  NASDAQ  |  Sep 03, 16:00
3.115 +0.04 (+1.14%) After-Hours: 20:00
More

Editas Medicine Research and Development Expense (Annual) : 84.68M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for EDIT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Research and Development Expense (Annual) Data

View and export this data back to 2015. Start Trial.
Date Value
December 31, 2025 84.68M
December 31, 2024 193.44M
December 31, 2023 171.59M
December 31, 2022 168.62M
December 31, 2021 137.45M
December 31, 2020 154.04M
Date Value
December 31, 2019 94.07M
December 31, 2018 90.65M
December 31, 2017 80.48M
December 31, 2016 55.78M
December 31, 2015 18.85M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Recursion Pharmaceuticals, Inc. 425.27M
Geron Corp. 71.43M
Halozyme Therapeutics, Inc. 81.49M
Novavax, Inc. 336.82M
AVITA Medical, Inc. 20.84M